Mylan N.V. (MYL) will pay $465 million to settle its EpiPen case, in which it misclassified the as a generic instead of a branded product. More
MYL
Recent Articles
Why Snap Inc (SNAP), J C Penney Company Inc (JCP) and Mylan N.V. (MYL) Are 3 of Today’s Worst Stocks
JCPenney (JCP), Snap (SNAP) and Mylan (MYL) shareholders couldn't wait for the trading week to come to a close. More
Mylan N.V. (MYL) Stock Hit by Forecast Cut
Mylan (MYL) stock was down today after the company cut its forecast for the year and missed estimates for the second quarter of 2017. More
10 Biotech Stocks With Game-Changing Dates in Q3
If you're looking to speculate in the inherent volatility of biotech stocks, here are ten impending events that could cause those fireworks. More
Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence
Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders? More
Adamis Pharmaceuticals Corp (ADMP) Stock Up, Then Down on Allergy Med
Adamis Pharmaceuticals (ADMP) shares soared as the company unveiled a medication to treat allergies that serves as an EpiPen alternative. More
Why Mylan N.V. (MYL), Cheesecake Factory Inc (CAKE) and Fossil Group Inc (FOSL) Are 3 of Today’s Worst Stocks
Mylan (MYL), Cheesecake Factory (CAKE) and Fossil Group (FOSL) couldn't win for losing on Tuesday. Here's what went wrong. More
